

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.¹

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**ELEVENTH MONTHLY FEE STATEMENT OF FTI CONSULTING, INC. FOR
COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF
EXPENSES INCURRED AS FINANCIAL ADVISOR TO THE AD HOC COMMITTEE
OF GOVERNMENTAL AND OTHER CONTINGENT LITIGATION CLAIMANTS FOR
THE PERIOD FROM AUGUST 1, 2020 THROUGH AUGUST 31, 2020**

Name of Applicant:	FTI Consulting, Inc.
Authorized to provide Professional Services to:	Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants
Date of Order Approving Debtors' Payment of Fees and Expenses of Applicant:	December 2, 2019 [ECF No. 553]
Period for which compensation and reimbursement is sought:	August 1, 2020 through August 31, 2020
Monthly Fees Incurred:	\$261,092.00

1. The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifesciences Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717), and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Monthly Expenses Incurred: \$108.25

Total Fees and Expenses Due: \$261,200.25

This is a: X monthly _____ interim _____ final application

PRIOR APPLICATIONS:

Docket No./Filed	Compensation Period	Requested		Approved	
		Fees	Expenses	Fees	Expenses
Docket No. 635 Filed On 12/9/2019	9/19/2019 – 10/31/2019	\$778,791.50	\$680.61	\$771,291.50	\$680.61
Docket No. 741 Filed On 1/13/2020	11/1/2019 – 11/30/2019	\$827,575.00	\$899.41	\$820,075.00	\$899.41
Docket No. 852 Filed on 2/20/2020	12/1/2019 – 12/31/2019	\$802,036.50	\$2,284.19	\$794,536.50	\$2,284.19
Docket No. 916 Filed on 3/12/2020	1/1/2020 – 1/31/2020	\$774,662.00	\$11,530.84	\$767,162.00	\$11,530.84
Docket No. 1090 Filed on 4/27/2020	2/1/2020 – 2/29/2020	\$615,089.00	\$6,141.22	\$610,714.00	\$6,141.22
Docket No. 1171 Filed on 5/19/2020	3/1/2020 – 3/31/2020	\$561,863.50	\$67.08	\$557,488.50	\$67.08
Docket No. 1251 Filed on 6/10/2020	4/1/2020 – 4/30/2020	\$428,303.00	\$1,732.28	\$423,928.00	\$1,732.28
Docket No. 1379 Filed on 7/13/2020	5/1/2020 – 5/31/2020	\$303,367.00	\$4,325.26	\$298,992.00	\$4,325.26
Docket No. 1651 Filed on 9/2/2020	6/1/2020 – 6/30/2020	\$374,753.00	\$96.90	\$ 299,802.60	\$ 96.90
Docket No. 1725 Filed on 9/25/2020	7/1/2020 – 7/31/2020	\$446,975.50	\$0.00	\$ -	\$ -

Note: The fee examiner's agreed upon reductions of \$30,000 and \$17,500 were allocated evenly across fees from the first and second interim period, respectively.

This statement (the "**Fee Statement**") of FTI Consulting, Inc. (together with its wholly owned subsidiaries and independent contractors, "**FTI**") as financial advisor to the Ad Hoc

Committee of Governmental and Other Contingent Litigation Claimants of Purdue Pharma L.P., *et al.* (the “**Committee**”) is submitted in accordance with the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals* [ECF No. 529] and the *Order Authorizing the Debtors to Assume the Reimbursement Agreement and Pay the Fees and Expenses of the Ad Hoc Committee’s Professionals* [ECF No. 553] entered on November 21, 2019 and December 2, 2019, respectively, (the “**Orders**”). In support of this Fee Statement, FTI respectfully states as follows.

1. The fees and expenses for the period from August 1, 2020 through and including August 31, 2020 (the “**Eleventh Fee Period**”) amount to:

Professional Fees	\$261,092.00
Expenses	<u>108.25</u>
TOTAL	<u>\$261,200.25</u>

2. In accordance with the Orders, FTI has separately recorded its fees in connection with or relating to the allocation of value among the Debtors’ creditors (the “**Allocation Fees**”) and has not, to the best of its knowledge, included Allocation Fees in this Fee Statement. If no timely and proper objection is made by a party-in-interest within fourteen (14) days after service of this Fee Statement, the Debtors are authorized to pay 80% of professional fees and 100% of out-of-pocket expenses. These amounts are presented below.

Professional Fees at 80%	\$208,873.60
Expenses at 100%	<u>108.25</u>
TOTAL	<u>\$208,981.85</u>

3. The professionals providing services, hourly billing rates, the aggregate hours worked by each professional, and the aggregate hourly fees for each professional during the Eleventh Fee Period are set forth on the schedule annexed hereto as **Exhibit “A.”**

4. A summary of aggregate hours worked and aggregate hourly fees for each task code during the Eleventh Fee Period is set forth on the schedule annexed hereto as **Exhibit “B.”**
5. Detailed time entry by task code during the Eleventh Fee Period is set forth on the schedule annexed hereto as **Exhibit “C.”**
6. A summary of expenses incurred during the Eleventh Fee Period is set forth on the schedule annexed hereto as **Exhibit “D.”**
7. Detailed breakdown of the expenses incurred during the Eleventh Fee Period is set forth on the schedule annexed hereto as **Exhibit “E.”**
8. FTI reserves the right to request, in subsequent fee statements and applications, reimbursement of any additional expenses incurred during the Eleventh Fee Period, as such expenses may not have been captured to date in FTI’s billing system.

NOTICE AND OBJECTION PROCEDURES

9. Objections to this Fee Statement, if any, must be filed with the Court and served upon the Notice Parties so as to be received no later than November 10, 2020 (the “**Objection Deadline**”), setting forth the nature of the objection and the amount of fees or expenses at issue (*an “**Objection**”*).
10. If no objections to this Fee Statement are filed and served as set forth above, the Debtors shall promptly pay eighty percent (80%) of the fees and one hundred percent (100%) of the expenses identified herein.
11. If an objection to this Fee Statement is received on or before the Objection Deadline, the Debtors shall withhold payment of that portion of this Fee Statement to which the objection is directed and promptly pay the remainder of the fees and disbursements in the percentages set forth above. To the extent such an objection is not resolved, it shall be

preserved and scheduled for consideration at the next interim fee application hearing to be heard by the Court.

Dated: New York, New York
October 26, 2020

FTI CONSULTING, INC.
Financial Advisors to the Ad Hoc Committee of
Governmental and Other Contingent Litigation
Claimants of Purdue Pharma L.P.

By: /s/ Matthew Diaz
Matthew Diaz, Senior Managing Director
Three Times Square, 10th Floor
New York, New York 10036
Telephone: (212) 499-3611
Email: matt.diaz@fticonsulting.com

EXHIBIT A
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
SUMMARY OF HOURS BY PROFESSIONAL
FOR THE PERIOD AUGUST 1, 2020 TO AUGUST 31, 2020

Professional	Position	Specialty	Billing Rate¹	Total Hours	Total Fees
Diaz, Matthew	Senior Managing Director	Restructuring	\$ 1,085	42.2	\$ 45,787.00
Greenblatt, Matthew	Senior Managing Director	Forensics	985	10.6	10,441.00
Joffe, Steven	Senior Managing Director	Tax	1,125	5.4	6,075.00
Simms, Steven	Senior Managing Director	Restructuring	1,295	1.1	1,424.50
Kyviakidis, Peter	Managing Director	Forensics	765	34.7	26,545.50
Nichols, David	Managing Director	Insurance	765	2.6	1,989.00
Shah, Jayshree	Senior Director	Healthcare	930	27.0	25,110.00
Suric, Emil	Senior Director	Healthcare	820	13.1	10,742.00
Costaldo, Nicole	Senior Director	Forensics	700	15.5	10,850.00
Bromberg, Brian	Director	Restructuring	815	88.8	72,372.00
Kim, Ye Darm	Senior Consultant	Restructuring	560	38.6	21,616.00
Mazzari, Meredith	Senior Consultant	Forensics	530	30.7	16,271.00
Kurtz, Emma	Consultant	Restructuring	415	28.6	11,869.00
GRAND TOTAL				338.9	\$ 261,092.00

1. Reflects blended hourly rates. Billing rates of international professionals have been translated to USD using the relevant spot rate.

EXHIBIT B

**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
SUMMARY OF HOURS BY TASK
FOR THE PERIOD AUGUST 1, 2020 TO AUGUST 31, 2020**

Task Code	Task Description	Total Hours	Total Fees
1	Current Operating Results & Events	16.4	\$ 12,166.00
7	Analysis of Domestic Business Plan	81.1	62,613.50
10	Analysis of Tax Issues	6.1	6,470.50
16	Analysis, Negotiate and Form of POR & DS	29.8	22,391.00
18	Review of Historical Transactions	128.5	94,920.50
19	Case Management	7.4	4,513.50
21	General Meetings with Counsel and/or Ad Hoc Committee	5.3	5,528.00
24	Preparation of Fee Application	7.2	4,791.00
28	Review of IAC Business Plan	57.1	47,698.00
GRAND TOTAL¹		338.9	\$ 261,092.00

1. Billing rates of international professionals have been translated to USD using the relevant spot rate.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD AUGUST 1, 2020 TO AUGUST 31, 2020

Task Category	Date	Professional	Hours	Activity
1	8/3/2020	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/3/2020	Kurtz, Emma	1.7	Prepare June YTD operating report update slides for the Committee.
1	8/4/2020	Diaz, Matthew	0.6	Review of Debtors' June operating results.
1	8/4/2020	Kurtz, Emma	0.7	Prepare revisions to June YTD operating report update for the Committee per internal comments.
1	8/10/2020	Diaz, Matthew	1.5	Detail review of the updated ANZ presentation and related analysis.
1	8/10/2020	Diaz, Matthew	2.8	Detail review of the report on the Debtors' business update and the recovery analysis.
1	8/10/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/11/2020	Diaz, Matthew	3.1	Detail review of the updated report to the committee on the June results, recovery analysis and the cash transfer analysis.
1	8/11/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/12/2020	Kurtz, Emma	0.5	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/13/2020	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/14/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/17/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/18/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/19/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/20/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/21/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/24/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/25/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/26/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/27/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/28/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/31/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1 Total			16.4	
7	8/3/2020	Diaz, Matthew	1.6	Review the Debtors' updated projections.
7	8/3/2020	Kim, Ye Darm	0.5	Review latest Adhansia/Foquest sales forecasts and compare to actual results.
7	8/3/2020	Kim, Ye Darm	1.1	Review Debtors' presentation to UCC re: YTD June results, CEO/CFO updates.
7	8/3/2020	Kim, Ye Darm	1.0	Review Debtors' dataroom updates for documents responsive to requests.
7	8/3/2020	Kurtz, Emma	0.3	Review updates to the distributable value report and June operating report.
7	8/3/2020	Bromberg, Brian	0.9	Review June YTD performance slides and provide revisions.
7	8/3/2020	Bromberg, Brian	1.5	Prepare domestic business update summary for distribution to team.
7	8/3/2020	Bromberg, Brian	2.3	Create draft template for analysis on domestic business plan.
7	8/3/2020	Bromberg, Brian	1.6	Review the Debtors' new business update presentation.
7	8/3/2020	Bromberg, Brian	0.5	Discuss the draft business plan analysis with internal team.
7	8/4/2020	Kim, Ye Darm	1.6	Compile Adhansia/Foquest sales data and prepare comparative analysis.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD AUGUST 1, 2020 TO AUGUST 31, 2020

Task Category	Date	Professional	Hours	Activity
7	8/4/2020	Bromberg, Brian	0.6	Provide revisions re: value scenario breakdown slides.
7	8/4/2020	Bromberg, Brian	1.1	Prepare draft outline re: value scenario breakdown slides.
7	8/4/2020	Bromberg, Brian	1.2	Prepare Purdue value scenario summary for presentation.
7	8/4/2020	Bromberg, Brian	0.9	Review June YTD performance slides and distribute overview to internal team.
7	8/4/2020	Bromberg, Brian	1.2	Review and provide revisions re: value scenario breakdown slides.
7	8/4/2020	Bromberg, Brian	0.7	Review ADHD product performance for the domestic company.
7	8/4/2020	Bromberg, Brian	0.9	Review comparison of ADHD products both internationally and domestically.
7	8/4/2020	Bromberg, Brian	2.8	Process revisions re: value scenario breakdown slides.
7	8/5/2020	Bromberg, Brian	0.5	Review business update presentation to screen for PEO information.
7	8/5/2020	Bromberg, Brian	0.7	Finalize value breakdown slides to send to team.
7	8/7/2020	Kim, Ye Darm	0.9	Review historical OxyContin sales forecasts to compare with new assumptions.
7	8/7/2020	Kim, Ye Darm	1.1	Review dataroom documents to identify potential sources of segment level historical performance.
7	8/7/2020	Bromberg, Brian	0.3	Finalize business update report to send to Houlihan Lokey for comments.
7	8/7/2020	Bromberg, Brian	0.9	Review Debtor-provided information on historical OxyContin figures.
7	8/7/2020	Bromberg, Brian	0.8	Review Debtors' updated OxyContin forecasts.
7	8/7/2020	Suric, Emil	1.1	Perform research to prepare internal OxyContin forecast analysis.
7	8/7/2020	Suric, Emil	1.9	Conduct preliminary OxyContin scenario based modeling.
7	8/7/2020	Suric, Emil	0.9	Review dataroom for documents re: OxyContin forecast modeling support.
7	8/9/2020	Diaz, Matthew	0.8	Review responses and related due diligence on the business plan update.
7	8/9/2020	Bromberg, Brian	0.7	Review historical financial information for Rhodes Pharma.
7	8/9/2020	Bromberg, Brian	0.5	Finalize PEO information list on business update presentation.
7	8/9/2020	Bromberg, Brian	1.8	Review newly uploaded dataroom documents re: product liability and bridges.
7	8/10/2020	Diaz, Matthew	0.5	Participate in call with Alix/PJT to discuss the liability reserves.
7	8/10/2020	Diaz, Matthew	0.8	Review the updated litigation costs estimates associated with the opioid business.
7	8/10/2020	Kim, Ye Darm	0.9	Process revisions to business update presentation re: royalty percentage updates.
7	8/10/2020	Kim, Ye Darm	1.2	Review historical financial files for product level actual results.
7	8/10/2020	Kim, Ye Darm	0.8	Prepare slide re: overview of expected go-forward liability assumptions.
7	8/10/2020	Kim, Ye Darm	1.1	Process revisions to domestic business update presentation per internal comments.
7	8/10/2020	Kurtz, Emma	0.9	Discuss internally re: business plan update and additional information to share.
7	8/10/2020	Bromberg, Brian	1.2	Review comments and process revisions to slides re: domestic business updates.
7	8/10/2020	Bromberg, Brian	1.2	Continue review and processing revisions to business update slides.
7	8/10/2020	Bromberg, Brian	0.7	Participate in discussion with team re: new domestic data from the Debtors.
7	8/10/2020	Bromberg, Brian	0.5	Review dataroom for updated sales information from the Debtors.
7	8/10/2020	Bromberg, Brian	1.0	Discuss business update presentation with Houlihan.
7	8/10/2020	Bromberg, Brian	2.8	Review and distribute draft business update slides to Counsel.
7	8/10/2020	Bromberg, Brian	0.5	Participate in discussion re: future product liabilities with Debtor advisors.
7	8/10/2020	Bromberg, Brian	0.5	Screen additional information included in business update slides for PEO information.
7	8/10/2020	Suric, Emil	1.5	Review dataroom for data on OxyContin and related research on competing products.
7	8/11/2020	Nichols, David	0.9	Perform assessment of Purdue's insurance coverage re: go-forward product liabilities.
7	8/11/2020	Diaz, Matthew	0.9	Review Purdue's go forward product liability insurance needs.
7	8/11/2020	Kim, Ye Darm	1.3	Process updates to business update presentation per internal comments.
7	8/11/2020	Bromberg, Brian	0.4	Clarify PEO/protective order issues for Counsel.
7	8/11/2020	Bromberg, Brian	0.9	Finalize business update presentation and distribute to Counsel.
7	8/11/2020	Bromberg, Brian	0.7	Incorporate revisions to business plan presentation.
7	8/11/2020	Bromberg, Brian	0.7	Discuss go-forward product liability insurance needs for Purdue with team.
7	8/12/2020	Kim, Ye Darm	1.2	Prepare revisions to the business update presentation per internal comments.
7	8/12/2020	Bromberg, Brian	0.7	Revise presentation for the Ad Hoc Committee update.
7	8/12/2020	Bromberg, Brian	0.6	Review new product price data provided in dataroom.
7	8/12/2020	Bromberg, Brian	0.5	Participate in advisors call to coordinate presentation for AHC meeting.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD AUGUST 1, 2020 TO AUGUST 31, 2020

Task Category	Date	Professional	Hours	Activity
7	8/13/2020	Bromberg, Brian	1.2	Review internal OxyContin forecast analysis and compare with Debtors' forecasts.
7	8/13/2020	Suric, Emil	2.2	Provide preliminary sensitivity forecasts of OxyContin to restructuring team and share follow up questions to Management on their assumptions in their base and upside case scenarios.
7	8/14/2020	Nichols, David	0.9	Participate in call re: analysis of Purdue's go-forward insurance options.
7	8/14/2020	Diaz, Matthew	0.5	Participate in a call with the Debtors to discuss their go forward insurance needs.
7	8/14/2020	Diaz, Matthew	0.9	Review the Company's historical insurance needs/assets in connection with reviewing go forward insurance practices.
7	8/14/2020	Bromberg, Brian	0.7	Participate in a call with the Debtors re: go forward insurance needs.
7	8/14/2020	Bromberg, Brian	1.2	Discuss and coordinate OxyContin forecast review with UCC Advisors.
7	8/14/2020	Bromberg, Brian	0.7	Discuss workplan for insurance diligence and transfers report.
7	8/14/2020	Suric, Emil	0.7	Review dataroom for information provided on Hysingla and Butrans for discussions with FTI team to share question list with management and to set up a call.
7	8/16/2020	Nichols, David	0.3	Participate in call with broker regarding product liability coverage.
7	8/17/2020	Bromberg, Brian	0.6	Finalize and send OxyContin forecast questions to Debtors.
7	8/18/2020	Kurtz, Emma	1.2	Prepare slides re: historical royalties payments between Purdue and the IACs and comparison to industry standards.
7	8/19/2020	Nichols, David	0.5	Participate in call with broker re: product liability coverage.
7	8/19/2020	Suric, Emil	1.4	Participate in due diligence call with Debtors on OxyContin and update sensitivity scenarios.
7	8/21/2020	Kurtz, Emma	2.1	Review documents received from Counsel re: historical financial information regarding Purdue, IACs, and Sacklers to prepare summary for team.
7	8/21/2020	Bromberg, Brian	0.5	Continue review of internal OxyContin forecast analysis and compare with Debtors' forecasts.
7	8/21/2020	Bromberg, Brian	0.9	Review the Debtors' response to UCC letter.
7	8/21/2020	Suric, Emil	0.6	Include downside case in sensitivity analysis for OxyContin forecasts.
7	8/24/2020	Bromberg, Brian	0.5	Review updated OxyContin forecast presentation.
7	8/31/2020	Bromberg, Brian	0.6	Discuss workplan with team re: OxyContin forecast diligence and insurance diligence.
7	8/31/2020	Suric, Emil	2.8	Conduct statistical and regression analyses of Xtampza conversion rate and prepare summary of findings.
7 Total			81.1	
10	8/6/2020	Joffe, Steven	0.5	Participate in discussion with internal team re: restitution.
10	8/6/2020	Joffe, Steven	1.5	Review NYSBA report on restitution for discussion purposes.
10	8/6/2020	Diaz, Matthew	0.5	Analyze tax consequences associated with the proposed settlement.
10	8/6/2020	Bromberg, Brian	0.7	Participate in discussion re: tax implications of IAC sale with internal team.
10	8/13/2020	Joffe, Steven	0.7	Participate in call with Kramer and Brown Rudnick re: tax considerations.
10	8/13/2020	Joffe, Steven	0.7	Participate in call with Davis Polk re: tax considerations.
10	8/13/2020	Bromberg, Brian	0.5	Participate in call with Kramer and Brown Rudnick re: tax considerations.
10	8/27/2020	Joffe, Steven	1.0	Call with Brown Rudnick and Kramer regarding tax considerations.
10 Total			6.1	
16	8/3/2020	Kim, Ye Darm	0.6	Review docket for claims filings re: Third Party Payors.
16	8/3/2020	Kim, Ye Darm	0.4	Participate in discussion re: updates to distributable value presentation.
16	8/4/2020	Kim, Ye Darm	1.2	Process revisions to distributable value update presentation per internal comments.
16	8/4/2020	Kim, Ye Darm	2.1	Prepare additional slides re: distributable value analysis update.
16	8/4/2020	Kim, Ye Darm	0.5	Participate in call re: distributable value update presentation.
16	8/4/2020	Kim, Ye Darm	2.3	Prepare draft distributable value update presentation.
16	8/4/2020	Diaz, Matthew	2.3	Review the updated waterfall recovery analysis and provide comments to internal team.
16	8/5/2020	Kim, Ye Darm	0.9	Prepare summary of PEO information relied upon in the distributable value update presentation.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD AUGUST 1, 2020 TO AUGUST 31, 2020

Task Category	Date	Professional	Hours	Activity
16	8/5/2020	Kim, Ye Darm	0.4	Process revisions to the distributable value update presentation.
16	8/7/2020	Kim, Ye Darm	0.5	Update list of PEO files relied on for distributable value analysis update presentation.
16	8/10/2020	Kim, Ye Darm	0.9	Update distributable value deck for information on historical Rhodes losses.
16	8/10/2020	Kim, Ye Darm	1.3	Process revisions to distributable value presentation for updated executive summary.
16	8/10/2020	Kim, Ye Darm	0.6	Process updates to the distributable value presentation.
16	8/10/2020	Kim, Ye Darm	2.3	Review Debtors' updates to new distributable value scenario estimates.
16	8/17/2020	Diaz, Matthew	1.6	Review the updated waterfall recovery analysis and provide comments to internal team.
16	8/17/2020	Diaz, Matthew	0.6	Participate on a call with Province to discuss their updated recovery analysis.
16	8/19/2020	Bromberg, Brian	1.7	Prepare slides on UCC distributable value analysis.
16	8/19/2020	Bromberg, Brian	3.2	Prepare response to UCC distributable value analysis.
16	8/19/2020	Bromberg, Brian	1.2	Participate in call with the AHC re: distributable value.
16	8/19/2020	Diaz, Matthew	1.7	Review slides on the updated recovery analysis.
16	8/21/2020	Bromberg, Brian	1.1	Revise slides on distributable value based on internal discussions.
16	8/21/2020	Bromberg, Brian	0.7	Discuss distributable value slides with team and Houlihan.
16	8/21/2020	Bromberg, Brian	1.3	Process revisions to slides re: distributable value.
16	8/28/2020	Bromberg, Brian	0.4	Review the updated distributable value analysis.
16 Total			29.8	
18	6/10/2020	Kyviakidis, Peter	0.5	Review proposed initial work plan and questions on investigatory work re: the Cash Transfers of Value Analysis and the Intercompany and Non-Cash Transfers Of Value.
18	6/11/2020	Kyviakidis, Peter	2.3	Review internal analyses re: the Cash Transfers of Value report.
18	6/12/2020	Kyviakidis, Peter	0.5	Participate on call to discuss certain observations re: internal analyses on the Cash Transfers of Value report.
18	6/15/2020	Kyviakidis, Peter	0.5	Participate on call to discuss the initial project work plan re: investigatory work on the Intercompany and Non-Cash Transfers of Value Analysis.
18	6/19/2020	Kyviakidis, Peter	1.8	Review internal analyses re: the Intercompany and Non-Cash Transfers of Value Analysis.
18	6/24/2020	Kyviakidis, Peter	1.3	Participate on call with AlixPartners re: nature and scope of AlixPartners's work procedures performed in connection with the information included in the Cash Transfers of Value Analysis.
18	6/25/2020	Kyviakidis, Peter	1.0	Participate on call with AlixPartners re: nature and scope of AlixPartners's work procedures performed in connection with the information included in the Intercompany and Non-Cash Value Transfers of Value Analysis.
18	6/29/2020	Kyviakidis, Peter	0.8	Participate on call to discuss information shared by AlixPartners re: Cash Transfers of Value Analysis and Intercompany and Non-Cash Transfers of Value Analysis.
18	6/29/2020	Kyviakidis, Peter	1.0	Discuss next steps per information shared by AlixPartners re: Cash Transfers of Value Analysis and Intercompany and Non-Cash Transfers of Value Analysis.
18	6/30/2020	Kyviakidis, Peter	1.3	Discuss workplan post-AlixPartners calls re: Cash Transfers of Value Analysis and Intercompany and Non-Cash Transfers of Value Analysis.
18	8/3/2020	Greenblatt, Matthew	1.0	Develop agenda and prepare for call with Province to discuss work performed to date and additional testing of AlixPartners' work product.
18	8/3/2020	Greenblatt, Matthew	0.6	Correspond with advisors and Province to coordinate workstreams and testing of AlixPartners' work product.
18	8/3/2020	Diaz, Matthew	0.9	Perform review of the cash transfers analysis.
18	8/3/2020	Bromberg, Brian	0.3	Confirm information sharing agreement with Counsel ahead of call with UCC.
18	8/4/2020	Mazzari, Meredith	1.0	Perform review and documentation of legal agreements governing select non-cash transfers.
18	8/5/2020	Greenblatt, Matthew	1.2	Participate in conference call with FTI team and the UCC professionals from Province to understand the testing of AlixPartners work and coordination of the parties collective efforts.
18	8/5/2020	Greenblatt, Matthew	0.9	Prepare agenda for call with UCC professionals from Province regarding work performed to date.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD AUGUST 1, 2020 TO AUGUST 31, 2020

Task Category	Date	Professional	Hours	Activity
18	8/5/2020	Diaz, Matthew	1.0	Participate in a call with Province to discuss the cash transfer analysis.
18	8/5/2020	Costaldo, Nicole	2.6	Prepare for, attend and debrief with team regarding the call with Province to discuss their diligence of the AlixPartners 1A and 1B reports.
18	8/5/2020	Mazzari, Meredith	1.8	Review and document of legal agreements governing select non-cash transfers.
18	8/5/2020	Mazzari, Meredith	1.1	Participate in conference call with FTI team and the UCC professionals from Province to understand the testing of AlixPartners work and coordination of the parties collective efforts.
18	8/5/2020	Mazzari, Meredith	1.0	Debrief with team regarding the call with Province to discuss their diligence of the AlixPartners 1A and 1B reports.
18	8/5/2020	Kyviakidis, Peter	1.0	Participate in conference call with FTI team and the UCC professionals from Province to understand the testing of AlixPartners work and coordination of the parties collective efforts.
18	8/5/2020	Kyviakidis, Peter	1.3	Participate in conference call with FTI team and the UCC professionals from Province to understand the testing of AlixPartners work and coordination of the parties collective efforts.
18	8/5/2020	Bromberg, Brian	1.1	Participate in call re: transfers of value with UCC advisors.
18	8/5/2020	Bromberg, Brian	0.4	Participate on call re: agenda for call with UCC professionals from Province regarding work performed to date.
18	8/6/2020	Costaldo, Nicole	1.1	Build out information requests and inquiries to further understand select transfers of the AlixPartners 1A and 1B reports.
18	8/7/2020	Diaz, Matthew	1.2	Review the updated draft of the transfers investigations report.
18	8/7/2020	Diaz, Matthew	0.5	Participate in call with the KL litigation team to discuss the cash and non-cash transfers analyses.
18	8/7/2020	Diaz, Matthew	0.5	Participate in call with Province to discuss the status of the investigation report.
18	8/7/2020	Costaldo, Nicole	1.4	Review of agreement inventory and continue to review 1B report to add information into the draft request list to be built out by FTI and Province
18	8/7/2020	Bromberg, Brian	1.8	Prepare outline and slides for transfer reports updates.
18	8/7/2020	Bromberg, Brian	0.5	Participate in discussion with team re: transfer report updates.
18	8/7/2020	Bromberg, Brian	0.5	Participate in call with the KL litigation team to discuss the cash and non-cash transfers analyses.
18	8/9/2020	Diaz, Matthew	0.9	Continue review of the updated draft of the transfers investigations report.
18	8/9/2020	Bromberg, Brian	1.0	Process revisions and finalize slides re: transfers of value updates.
18	8/10/2020	Costaldo, Nicole	1.6	Conference with team re: review of the audited financial statements to determine cash balance per financial statements for analysis of funds distributed and identified by AlixPartners.
18	8/10/2020	Kyviakidis, Peter	0.8	Participate in internal discussion re: reconciliation of cash available to pay distributions to the owners of the Debtor Entities over the time period of 2008 through 2017.
18	8/11/2020	Costaldo, Nicole	3.1	Document key metrics and continue to review of the audited financial statements for Purdue and Rhodes.
18	8/12/2020	Greenblatt, Matthew	1.0	Continue reconciliation of the cash distributions to the Sacklers in the audited financials to the AlixPartners report.
18	8/12/2020	Costaldo, Nicole	2.1	Update analysis re: cash on hand for distributions and how that number compares to the amount of funds distributed and identified by AlixPartners in the 1A report.
18	8/12/2020	Kyviakidis, Peter	1.0	Provide revisions re: reconciliation of cash available to pay distributions to owners of the Debtor Entities over the time period of 2008 through 2017.
18	8/13/2020	Diaz, Matthew	1.5	Review of the Sackler cash and non cash transfer analysis provided by Milbank and Huron.
18	8/13/2020	Diaz, Matthew	0.8	Participate in a call with Milbank and Huron to discuss the cash and non cash transfer report.
18	8/13/2020	Bromberg, Brian	0.8	Participate in a call with Milbank and Huron to discuss the cash and non cash transfer report.
18	8/14/2020	Diaz, Matthew	0.9	Review the Sackler report on the cash and non cash transfers and related next steps.
18	8/14/2020	Kim, Ye Darm	2.2	Review Raymond-side non cash activity presentation and summary.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD AUGUST 1, 2020 TO AUGUST 31, 2020

Task Category	Date	Professional	Hours	Activity
18	8/14/2020	Bromberg, Brian	2.5	Review Raymond-side non cash activity presentation and summary.
18	8/17/2020	Kurtz, Emma	1.8	Prepare revisions to analysis re: historical transfers between Sackler entities to prepare slides re: cash transfers and net investments by entity.
18	8/17/2020	Kurtz, Emma	1.7	Prepare Sackler entity organizational chart to track cash flows between them and outside the network.
18	8/17/2020	Bromberg, Brian	1.9	Prepare slides summarizing B side report.
18	8/17/2020	Bromberg, Brian	1.7	Review non-cash transfers presentation and prepare summary for internal distribution.
18	8/18/2020	Greenblatt, Matthew	1.2	Continue review of the AlixPartners Cash Transfers Report and further reconciliation between the Alix report and the audited financial statements.
18	8/19/2020	Greenblatt, Matthew	1.8	Participate in discussions with team and continue summary of observations and development of proposed next steps for review and testing of the AlixPartners Cash Transfers Reports.
18	8/19/2020	Costaldo, Nicole	1.4	Attend call with team to go over the results of the analysis to determine the cash available after distributions when compared to AlixPartners' Cash Transfers of Value report.
18	8/19/2020	Mazzari, Meredith	0.6	Participate in internal discussion re: reconciliation of cash available to distributions for the relevant period.
18	8/19/2020	Mazzari, Meredith	2.6	Prepare reconciliation of cash distributions by Purdue and Rhodes.
18	8/19/2020	Mazzari, Meredith	0.8	Participate in internal discussion re: reconciliation of cash available to distributions for the relevant period.
18	8/19/2020	Kyviakidis, Peter	1.8	Participate in discussion with team re: summary of observations and next steps re: testing of the AlixPartners Cash Transfers Reports.
18	8/19/2020	Kyviakidis, Peter	1.5	Attend call with team to go over the results of the analysis to determine the cash available after distributions when compared to AlixPartners' Cash Transfers of Value report.
18	8/19/2020	Bromberg, Brian	2.2	Review and prepare additional diligence items to supplement UCC questions on B side transfer report.
18	8/20/2020	Diaz, Matthew	1.1	Review the updated cash reconciliation analysis versus the dividends received by the Sacklers.
18	8/20/2020	Costaldo, Nicole	1.8	Continue conference with team regarding the reconciling items per FTI and AlixPartners' review of the partners cash distributions from Purdue and Rhodes.
18	8/20/2020	Mazzari, Meredith	2.2	Participate in internal meeting re: revisions to preliminary reconciliation of cash distributions.
18	8/20/2020	Mazzari, Meredith	0.4	Draft email on status of reconciliation of cash distributions.
18	8/20/2020	Mazzari, Meredith	0.4	Revise reconciliation of cash distributions.
18	8/20/2020	Mazzari, Meredith	0.6	Review updates to analysis of reconciliation of cash distributions.
18	8/20/2020	Mazzari, Meredith	1.8	Continue conference with team regarding the reconciling items per FTI and AlixPartners' review of the partners cash distributions from Purdue and Rhodes.
18	8/20/2020	Kyviakidis, Peter	0.8	Prepare for call to discuss a preliminary reconciliation of cash available to pay distributions over the time period of 2008 through 2017.
18	8/20/2020	Kyviakidis, Peter	1.5	Review updated version of analysis re: reconciliation of cash available to pay distributions over the time period of 2008 through 2017.
18	8/20/2020	Kyviakidis, Peter	2.3	Participate in internal meeting re: revisions to preliminary reconciliation of cash distributions.
18	8/20/2020	Bromberg, Brian	1.2	Review the Sackler net asset reports.
18	8/20/2020	Bromberg, Brian	0.8	Prepare slides for business update re: update on transfers diligence.
18	8/20/2020	Bromberg, Brian	1.2	Prepare additional diligence questions to supplement UCC question list for shareholders on transfers.
18	8/24/2020	Greenblatt, Matthew	1.2	Review summary of open items and reconciling items between Alix Report and Audited Financial Statements.
18	8/24/2020	Costaldo, Nicole	0.4	Discuss the results of the analysis of the reconciling items per AlixPartners Cash Transfers of Value report.
18	8/24/2020	Mazzari, Meredith	0.4	Attend call with forensic accounting team to discuss the results of the analysis of the reconciling items per AlixPartners Cash Transfers of Value report.
18	8/24/2020	Mazzari, Meredith	0.8	Participate in internal call re: updates to reconciliation of cash distributions.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD AUGUST 1, 2020 TO AUGUST 31, 2020

Task Category	Date	Professional	Hours	Activity
18	8/24/2020	Mazzari, Meredith	0.6	Participate in discussion re: reconciliation of cash distributions
18	8/24/2020	Mazzari, Meredith	0.9	Revise reconciliation of cash distributions.
18	8/24/2020	Kyviakidis, Peter	0.8	Participate in internal call re: updates to reconciliation of cash distributions.
18	8/24/2020	Kyviakidis, Peter	0.5	Participate in discussion re: reconciliation of cash distributions
18	8/24/2020	Kyviakidis, Peter	0.5	Attend call with forensic accounting team to discuss the results of the analysis of the reconciling items per AlixPartners Cash Transfers of Value report.
18	8/25/2020	Mazzari, Meredith	0.3	Participate in internal call re: reconciliation of cash distributions memo.
18	8/25/2020	Mazzari, Meredith	1.5	Participate in internal call re: updates to reconciliation of cash distributions memo.
18	8/25/2020	Mazzari, Meredith	0.7	Revise reconciliation of cash distributions.
18	8/25/2020	Mazzari, Meredith	0.4	Participate in internal call re: revisions to reconciliation of cash distributions memo.
18	8/25/2020	Mazzari, Meredith	0.6	Participate in internal call re: revisions to reconciliation of cash distributions memo.
18	8/26/2020	Mazzari, Meredith	2.5	Participate on call to revise preliminary reconciliation of cash available for distributions.
18	8/26/2020	Mazzari, Meredith	0.3	Quality check review of reconciliation of cash distributions memo.
18	8/26/2020	Mazzari, Meredith	1.2	Participate in internal call re: revisions to reconciliation of cash distributions memo.
18	8/26/2020	Mazzari, Meredith	1.1	Participate in internal call re: revisions to reconciliation of cash distributions memo.
18	8/26/2020	Mazzari, Meredith	0.7	Participate in internal call re: revisions to reconciliation of cash distributions memo.
18	8/26/2020	Mazzari, Meredith	0.6	Process revisions to reconciliation of cash distributions memo.
18	8/26/2020	Mazzari, Meredith	0.4	Continue processing revisions to reconciliation of cash distributions memo.
18	8/26/2020	Mazzari, Meredith	0.9	Participate in internal call re: revisions to reconciliation of cash distributions memo.
18	8/26/2020	Mazzari, Meredith	2.5	Participate on call to revise preliminary reconciliation of cash available for distributions.
18	8/26/2020	Kyviakidis, Peter	0.8	Participate in internal call re: revisions to reconciliation of cash distributions memo.
18	8/26/2020	Kyviakidis, Peter	2.5	Participate on call to revise preliminary reconciliation of cash available for distributions.
18	8/26/2020	Kyviakidis, Peter	1.3	Participate in internal call re: revisions to reconciliation of cash distributions memo.
18	8/26/2020	Kyviakidis, Peter	3.0	Participate on call to revise preliminary reconciliation of cash available for distributions.
18	8/26/2020	Kyviakidis, Peter	1.0	Participate in internal call re: revisions to reconciliation of cash distributions memo.
18	8/26/2020	Kyviakidis, Peter	0.3	Participate in internal call re: revisions to reconciliation of cash distributions memo.
18	8/26/2020	Kyviakidis, Peter	1.0	Participate in internal call re: revisions to reconciliation of cash distributions memo.
18	8/27/2020	Greenblatt, Matthew	1.7	Finalize review and circulate summary memorandum of open items for the comparison between the Alix Partners report and the audited financial statements.
18	8/27/2020	Bromberg, Brian	1.1	Participate in call with Huron re: Side B transfers.
18	8/27/2020	Bromberg, Brian	0.3	Prepare summarize of diligence call with Huron re: Side B transfers.
18	8/31/2020	Diaz, Matthew	0.4	Review the Sackler deposition summary.
18	8/31/2020	Bromberg, Brian	1.5	Participate call with Committee re: mediation issues and discovery review.
18	8/31/2020	Bromberg, Brian	0.8	Review the latest financial discovery documents.
18 Total			128.5	
19	8/3/2020	Simms, Steven	0.4	Participate in correspondence on open case items and ongoing workstreams.
19	8/3/2020	Kurtz, Emma	0.8	Prepare updates to the dataroom index to include recently uploaded documents to share with team.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD AUGUST 1, 2020 TO AUGUST 31, 2020

Task Category	Date	Professional	Hours	Activity
19	8/10/2020	Kurtz, Emma	0.7	Prepare update to dataroom index to include recently shared documents to update team.
19	8/14/2020	Diaz, Matthew	0.6	Review of open and outstanding case issues and related next steps for diligence.
19	8/18/2020	Kurtz, Emma	0.4	Prepare updates to dataroom index to incorporate recently uploaded documents to share with team.
19	8/20/2020	Kurtz, Emma	0.4	Update dataroom index to include recently uploaded documents to share with team.
19	8/25/2020	Simms, Steven	0.4	Participate in discussion re: updates on case status.
19	8/25/2020	Simms, Steven	0.3	Participate in correspondence on case items related to UCC issues.
19	8/27/2020	Kurtz, Emma	1.1	Prepare updates to dataroom index to incorporate recently uploaded documents to share with team.
19	8/31/2020	Kim, Ye Darm	0.5	Discuss ongoing case work streams and upcoming deliverables to the Committee with internal team.
19	8/31/2020	Kurtz, Emma	1.2	Update dataroom index to include recently uploaded documents to share with team.
19	8/31/2020	Kurtz, Emma	0.6	Discuss ongoing case work streams and upcoming deliverables to the Committee with internal team.
19 Total			7.4	
21	8/12/2020	Diaz, Matthew	0.7	Prepare for the weekly call with the AHC.
21	8/12/2020	Diaz, Matthew	1.8	Perform detailed review of the updated presentation to the AHC on business update, recovery analysis and transfers analysis for the weekly meeting.
21	8/12/2020	Kim, Ye Darm	0.5	Participate in pre-call for the weekly committee call re: business update presentation.
21	8/19/2020	Joffe, Steven	1.0	Participate in call with AHC re: tax considerations.
21	8/31/2020	Diaz, Matthew	1.3	Participate in the call with the AHC re: case updates and issues.
21 Total			5.3	
24	8/3/2020	Kim, Ye Darm	2.6	Process revisions to draft June Fee application.
24	8/6/2020	Kim, Ye Darm	0.8	Process revisions to June fee application draft.
24	8/7/2020	Diaz, Matthew	0.8	Review the June bill.
24	8/7/2020	Kim, Ye Darm	0.6	Prepare update tracker of historical billing and receipts.
24	8/12/2020	Diaz, Matthew	0.5	Review of the June fee statement.
24	8/12/2020	Kim, Ye Darm	1.6	Prepare final version of the June Fee application.
24	8/25/2020	Bromberg, Brian	0.3	Review latest June FTI fee application.
24 Total			7.2	
28	8/3/2020	Diaz, Matthew	1.8	Review the updated responses to questions on the IAC analysis and related diligence.
28	8/3/2020	Bromberg, Brian	1.2	Review dataroom for ADHD product information.
28	8/3/2020	Bromberg, Brian	0.9	Review ADHD product performance for IACs.
28	8/6/2020	Bromberg, Brian	1.8	Review diligence responses provided on Canadian financials in dataroom.
28	8/6/2020	Bromberg, Brian	0.5	Coordinate with Counsel re: non-reliance letter comments.
28	8/10/2020	Bromberg, Brian	1.3	Review IAC royalty agreements re: licensing agreement diligence.
28	8/10/2020	Bromberg, Brian	0.5	Discuss IAC diligence letter with Debtor and UCC advisors.
28	8/11/2020	Kurtz, Emma	3.2	Review historical IAC licensing agreements to prepare analysis of terms, including royalty rates.
28	8/11/2020	Bromberg, Brian	0.5	Review letter to IACs for discussion with Debtors and UCC advisors.
28	8/11/2020	Bromberg, Brian	0.6	Review IAC licensing agreements diligence status with team.
28	8/11/2020	Bromberg, Brian	1.3	Review IAC licensing agreements re: market royalty rates.
28	8/11/2020	Shah, Jayshree	3.1	Conduct research to understand the relationship between Purdue and Mundi IACs from a licensing perspective to benchmark against market.
28	8/12/2020	Shah, Jayshree	1.9	Continue research to understand the relationship between Purdue and Mundi IACs from a licensing perspective to benchmark against market.
28	8/12/2020	Shah, Jayshree	3.0	Continue research to understand the relationship between Purdue and Mundi IACs from a licensing perspective to benchmark against market.
28	8/13/2020	Bromberg, Brian	1.6	Review updated draft of IAC licensing agreement summary analysis.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD AUGUST 1, 2020 TO AUGUST 31, 2020

Task Category	Date	Professional	Hours	Activity
28	8/13/2020	Shah, Jayshree	2.2	Review primary and secondary research conducted re: IAC licensing agreements.
28	8/13/2020	Shah, Jayshree	3.8	Conduct primary and secondary research re: IAC licensing agreement royalty rates.
28	8/14/2020	Diaz, Matthew	1.2	Review the transfer pricing policies between the IACs and Purdue.
28	8/14/2020	Diaz, Matthew	0.3	Review the letter to the IAC management re: open due diligence.
28	8/14/2020	Kim, Ye Darm	0.6	Review licensing agreements summary analysis to prepare for call.
28	8/14/2020	Kim, Ye Darm	0.6	Participate on call re: OxyContin licensing with Mundipharma.
28	8/14/2020	Kim, Ye Darm	0.9	Review questions list re: market/product prepared by UCC advisors.
28	8/14/2020	Kim, Ye Darm	1.0	Review royalty percentages analysis prepared by UK team.
28	8/14/2020	Kurtz, Emma	0.5	Review comparable companies royalty rates to evaluate IAC licensing agreements.
28	8/14/2020	Kurtz, Emma	0.4	Update outstanding IAC business plan diligence request list to incorporate additional questions sent to Company.
28	8/14/2020	Bromberg, Brian	0.5	Participate in discussion re: licensing agreements diligence with internal team.
28	8/14/2020	Shah, Jayshree	2.0	Prepare and participate in meeting with US FTI team to discuss perspective on royalty fees.
28	8/17/2020	Shah, Jayshree	3.2	Review license agreements for Oxycontin and Oxycontin tamper proof to understand royalty rate comps.
28	8/17/2020	Shah, Jayshree	2.8	Continue review of license agreements for Oxycontin and Oxycontin tamper proof to understand royalty rate comps.
28	8/18/2020	Kurtz, Emma	0.4	Review diligence responses received from the Company re: central functions to evaluate responsiveness to outstanding questions.
28	8/18/2020	Bromberg, Brian	0.7	Review IAC diligence re: central functions responsiveness.
28	8/18/2020	Shah, Jayshree	3.0	Continue review of license agreements for Oxycontin and Oxycontin tamper proof to understand royalty rate comps.
28	8/19/2020	Kurtz, Emma	0.9	Review recent diligence responses from Company and additional questions submitted to update outstanding diligence request list.
28	8/19/2020	Shah, Jayshree	2.0	Continue review of license agreements for Oxycontin and Oxycontin tamper proof to understand royalty rate comps.
28	8/20/2020	Bromberg, Brian	0.8	Prepare slides for business update re: licensing agreement diligence.
28	8/24/2020	Bromberg, Brian	0.5	Review and discuss non reliance letter with Huron.
28	8/26/2020	Kurtz, Emma	0.9	Review Steve Jamieson diligence responses to evaluate responsiveness to outstanding questions.
28	8/26/2020	Kurtz, Emma	0.3	Update outstanding diligence request list to reflect latest responses from the Company.
28	8/28/2020	Diaz, Matthew	1.4	Review the updated IAC due diligence on licensing agreements.
28	8/28/2020	Kurtz, Emma	0.4	Review diligence responses from the Company re: central functions.
28	8/31/2020	Diaz, Matthew	1.4	Review responses from IAC re: outstanding diligence questions.
28	8/31/2020	Bromberg, Brian	1.2	Review information provided by IACs re: outstanding diligence requests.
28 Total			57.1	
Grand Total			338.9	

EXHIBIT D

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

SUMMARY OF EXPENSES

FOR THE PERIOD AUGUST 1, 2020 TO AUGUST 31, 2020

Expense Type	Amount¹
Other	\$ 108.25
Grand Total	\$ 108.25

EXHIBIT E

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

EXPENSE DETAIL

FOR THE PERIOD AUGUST 1, 2020 TO AUGUST 31, 2020

Date	Professional	Expense Type	Expense Detail	Amount
8/18/2020	Bromberg, Brian	Other	Court Call Charges - participated in telephonic court hearing	\$ 38.25
8/26/2020	Diaz, Matthew	Other	Court Call Charges - participated in telephonic court hearing	\$ 70.00
Other Total				\$ 108.25
Grand Total				\$ 108.25